Quest Diagnostics Q2 revenue rises 10.2%, adjusted EPS up 19.1%, raises full-year guidance

Quest Diagnostics reported a 10.2% increase in second-quarter revenues to $3.04 billion, driven by 10% organic growth. Adjusted diluted earnings per share rose 19.1% to $3.12, reflecting strong demand across physician, hospital, and consumer channels. The company raised its full-year 2026 revenue guidance to $11.95-$12.05 billion and adjusted EPS guidance to $11.05-$11.25, citing continued innovation and operational improvements. This growth highlights Quest's expanding role in advanced diagnostics and collaborations in kidney care and cancer testing.